The ZERO Childhood Cancer program is a national study exploring the feasibility of comprehensive genome profiling of high-risk childhood cancers as a means to identify new therapy opportunities for children with few options available to them. The evidence from the ZERO study, and similar studies around the world, indicate that genomics can lead to improved patient outcomes. But there are other important lessons we are learning, including the important roles that preclinical experimental data might have in helping clinical decision making.
Associate Professor Ekert research interests include the molecular biology and therapeutic targeting of genomic drivers in paediatric cancer, with a focus on fusion oncogenes. He will will present on Lessons from the ZERO Childhood Cancer precision medicine program.
Associate Professor Paul Ekert is the Group Leader of the Translational Tumour Biology at the Children’s Cancer Institute, UNSW and is cross appointed at the Peter MacCallum Cancer Centre and Murdoch Children’s Research Institute.
